Holen Sie sich die Stockscreener-App
52.84
4.26%
2.16
Handel nachbörslich:
52.93
0.09
+0.17%
Schlusskurs vom Vortag:
$50.68
Offen:
$50.59
24-Stunden-Volumen:
5.35M
Relative Volume:
0.52
Marktkapitalisierung:
$20.96B
Einnahmen:
$1.94B
Nettoeinkommen (Verlust:
$-2.82B
KGV:
-7.2765
EPS:
-7.2617
Netto-Cashflow:
$-2.08B
1W Leistung:
+5.45%
1M Leistung:
+0.53%
6M Leistung:
+101.30%
1J Leistung:
+97.16%
1-Tages-Spanne:
$50.05
$53.00
1-Wochen-Bereich:
$50.02
$53.00
52-Wochen-Spanne:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
52.84 | 20.21B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna Impfstoff (Spikevax): Pivot to Cancer Vaccines Reshapes Future - AD HOC NEWS
Moderna Inc. stock (US60770K1034): Is mRNA pipeline expansion strong enough to unlock new upside? - AD HOC NEWS
3 Unpopular Stocks We Approach with Caution - The Globe and Mail
MRNA SEC FilingsModerna 10-K, 10-Q, 8-K Forms - Stock Titan
Moderna Inc. stock (US60770K1034): Is the pivot beyond COVID vaccines now the real test? - AD HOC NEWS
Moderna Impfstoff (Spikevax): Respiratory Vaccine Pivot Could Reshape mRNA Future - AD HOC NEWS
Moderna (MRNA) Sees Positive Momentum with Earnings Ahead - GuruFocus
Moderna Impfstoff (Spikevax): mRNA Pivot Beyond COVID Fuels Uncertain Path - AD HOC NEWS
Baillie Gifford & Co. Sells 1,266,152 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock (MRNA) Opinions on FDA Flu Vaccine Review - Quiver Quantitative
Best Biotech Stocks To Keep An Eye OnApril 12th - MarketBeat
Segovias de Estelí Returns to Germany via Tradición Moderna, Announces InterTabac Exclusive Release - halfwheel
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
Promising Biotech Stocks To Follow TodayApril 10th - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Douglas Lane & Associates LLC - MarketBeat
What is behind Moderna stock's recent drop in value today - Traders Union
Moderna Inc (MRNA) Stock Price Quote Today & Current Price Chart - Capital.com
MODERNA, INC. (MRNA) - MSN
Moderna (MRNA) Experiences Bullish Trading Activity - GuruFocus
Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension - Yahoo Finance
Looks Like M&A Week in 3 Different Sectors - The Motley Fool
Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy? - Yahoo Finance
Moderna eyes international markets as growth driver, says Bank of America - Proactive financial news
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo Finance UK
(MRNA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Messenger RNA (mRNA) Market Projected to Reach $20.99 - GlobeNewswire
Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas - Yahoo Finance
Moderna stock consolidates as short-term sellers dominate near $53.35 resistance - Traders Union
RBC Adjusts Price Target on Moderna to $35 From $30, Maintains Sector Perform Rating - marketscreener.com
Spikevax Vaccine: Key Role in mRNA COVID Protection - AD HOC NEWS
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 - Investing News Network
New Moderna data tests repeat flu and RSV shots in older adults - Stock Titan
Moderna (MRNA) CFO vests RSUs, 703 shares withheld for tax - Stock Titan
Moderna: Speculative Buy For Aggressive Investors Betting On mRNA's Future (NASDAQ:MRNA) - Seeking Alpha
Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes - Insider Monkey
Is Moderna (MRNA) Pricing Make Sense After A 96% One Year Share Price Jump - Yahoo Finance
Moderna Inc (MRNA) - MSN
Top Moderna Shareholders - Investopedia
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
Moderna (MRNA) stock dips while market gains: Key facts - MSN
Moderna says the FDA will consider its new flu shot after resolving a public dispute - Dayton Daily News
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Moderna (NASDAQ:MRNA) Target Update Sparks Nasdaq 100 Index Focus - Kalkine Media
Barclays Analyst Raises Price Target for Moderna (MRNA) to $48.0 - GuruFocus
Moderna (NASDAQ:MRNA) Price Target Raised to $48.00 at Barclays - MarketBeat
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment - BioSpace
Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Moderna, Inc. Trade Ideas — BSESOF:0QF - TradingView
What's Going On With Pfizer Stock Wednesday?BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE) - Benzinga
Moderna, Inc. Trade Ideas — EUROTLX:4MRNA - TradingView — Track All Markets
Barclays Adjusts Price Target on Moderna to $48 From $25, Maintains Equalweight Rating - marketscreener.com
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):